We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
β-blockers: a novel class of antitumor agents.
- Authors
Yi Ji; Siyuan Chen; Xianmin Xiao; Shan Zheng; Kai Li
- Abstract
β-adrenergic signaling modulates key signaling pathways that are important for tumor-promoting processes, and numerous mechanisms of action have been elucidated. Preclinical studies have demonstrated that β-adrenergic antagonists, or β-blockers, can block multiple fundamental biologic processes underlying the progression and metastasis of tumors, including the inhibition of cell proliferation, migration, invasion, resistance to programmed cell death, and tumor angiogenesis and metastasis. Human pharmacoepidemiologic studies suggest that β-blockers have a role in inhibiting cancer progression and metastasis in combination with standard therapies. Furthermore, a number of prospective studies have demonstrated that β-blockers are effective at halting infantile hemangioma growth. These findings shed light on the novel perspective of using β-blockers as a class of potential antitumor agents in clinical oncology.
- Subjects
ADRENERGIC beta blockers; ANTINEOPLASTIC agents; CANCER invasiveness; METASTASIS; TUMOR prevention; CELL proliferation; CELL death; PREVENTION
- Publication
OncoTargets & Therapy, 2012, Vol 5, p391
- ISSN
1178-6930
- Publication type
Article
- DOI
10.2147/OTT.S38403